Specify a stock or a cryptocurrency in the search bar to get a summary
MoonLake Immunotherapeutics
MLTXMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. Address: Dorfstrasse 29, Zug, Switzerland, 6300
Analytics
WallStreet Target Price
71.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MLTX
Dividend Analytics MLTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MLTX
Stock Valuation MLTX
Financials MLTX
Results | 2019 | Dynamics |